On this page
KIF1A-associated neurological disorder
This condition can cause issues with movement, balance, and cognitive development, and its severity can vary. It is caused by changes in the KIF1A gene and can affect individuals from infancy or early childhood.
Overview
KIF1A-associated neurological disorder (KAND) is a rare inherited condition that affects the brain and spinal cord, which together form the central nervous system. Individuals with KAND can experience a range of symptoms, including difficulties with movement, muscle stiffness or weakness, and developmental delays. The condition is progressive, meaning symptoms can worsen over time. While KAND presents differently among affected individuals, the core features relate to neurological function [PMID:33675003]. This condition is often diagnosed in infancy or early childhood, although some individuals may present later.
Symptoms & clinical features
The symptoms of KAND are varied and can affect many aspects of neurological function. Common features include spasticity (muscle stiffness), ataxia (problems with coordination and balance), and intellectual disability. Other reported symptoms may include optic atrophy (degeneration of the nerve connecting the eye to the brain), epilepsy, and issues with speech and feeding. The severity and combination of these symptoms can differ significantly between individuals, even within the same family [PMID:33675003]. For instance, some individuals might experience severe mobility challenges from a young age, while others may have milder symptoms that emerge later in life. Vision problems, such as nystagmus (involuntary eye movements) and strabismus (misalignment of the eyes), are also frequently observed.
Video: Genetics 101
Affected organs
KAND primarily affects the central and peripheral nervous systems. The brain and spinal cord are the most significantly impacted, leading to motor difficulties, cognitive impairment, and problems with coordination. The optic nerves, which transmit visual information from the eyes to the brain, can also be affected, leading to optic atrophy and visual impairment. In some cases, nerve damage can extend to the peripheral nerves, which are outside the brain and spinal cord, contributing to muscle weakness and sensory issues [PMID:33675003].
Risks & severity
The severity of KAND can range from mild to severe, with a significant impact on an individual's quality of life. The condition is typically progressive, meaning that symptoms can worsen over time, though the rate of progression varies. Most individuals experience symptoms from infancy or early childhood. Intellectual disability is common, ranging from mild learning difficulties to severe cognitive impairment. The risk of developing specific neurological complications, such as epilepsy or severe motor impairment, depends on the particular genetic change in KIF1A and other individual factors. Due to its rarity, the exact prevalence of KAND is not well established.
Genetic causes
KIF1A-associated neurological disorder is caused by genetic changes (pathogenic variants) in the KIF1A gene. The KIF1A gene provides instructions for making a protein called kinesin family member 1A. This protein is a motor protein, which means it helps transport essential materials and components, such as neurotransmitters and mitochondria, along nerve cells (neurons) [PMID:28751532]. This transportation process is crucial for the proper development, function, and survival of neurons, particularly in long axons. Pathogenic variants in KIF1A can disrupt this vital transport system, leading to the accumulation of waste products or the failure to deliver necessary materials, ultimately impairing nerve function and causing the neurological symptoms seen in KAND.
- KIF1A kinesin family member 1A
Inheritance pattern
KAND can be inherited in two main ways: autosomal dominant or autosomal recessive. In autosomal dominant inheritance, only one copy of the altered KIF1A gene is needed to cause the condition. This means an affected individual has a 50% chance of passing the condition to each of their children. Autosomal recessive inheritance requires two altered copies of the KIF1A gene, one from each parent, for a person to be affected. Parents who each carry one altered copy are typically unaffected but have a 25% chance with each pregnancy of having a child with KAND. The inheritance pattern for a specific family will be determined by the nature of the genetic changes identified.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
Diagnosis & testing
Diagnosis of KIF1A-associated neurological disorder is confirmed through genetic testing, which identifies pathogenic variants in the KIF1A gene. Clinical suspicion often arises from a combination of characteristic neurological symptoms, such as developmental delay, spasticity, or ataxia. Referral for genetic testing is typically made by a paediatrician, neurologist, or clinical geneticist. In the UK, genetic testing for suspected neurological disorders, including those related to KIF1A, is available through the NHS Genomic Medicine Service. The relevant NHS National Genomic Test Directory R-codes (e.g., R350 Developmental disorders, R353 Movement disorders) guide which genetic tests are appropriate based on the presenting symptoms. Genetic counsellors can provide support and information regarding testing options and results.
Management & lifestyle
Management of KAND focuses on addressing individual symptoms and providing supportive care to improve quality of life. There is currently no cure for KAND, so treatment strategies are aimed at managing symptoms as they arise. This often involves a multidisciplinary team, including neurologists, physiotherapists, occupational therapists, speech and language therapists, and ophthalmologists. Physiotherapy can help manage spasticity and improve motor skills, while occupational therapy assists with daily living activities. Medications may be used to control symptoms such as epilepsy or severe spasticity. Regular follow-up appointments allow healthcare professionals to monitor the progression of the condition and adjust interventions as needed. Genetic counsellors can also provide ongoing support for families.
UK care pathway
In the UK, individuals suspected of having a rare genetic condition like KAND are typically referred to clinical genetics services. These services are part of the NHS Genomic Medicine Service (GMS), which provides comprehensive genomic testing and interpretation. A clinical geneticist or a paediatric neurologist would usually initiate genomic testing, guided by the NHS National Genomic Test Directory R-codes. Following diagnosis, patients and their families have access to genetic counsellors who can explain the genetic findings, discuss inheritance patterns, and provide psychological support. Ongoing care is managed through NHS specialist clinics and local healthcare teams.
Frequently asked questions
What does KIF1A do in the body?
The KIF1A gene provides instructions for a protein that acts like a 'motor' inside nerve cells. This motor protein is essential for moving important materials, such as neurotransmitters and other cellular components, along the long extensions of nerve cells. This transport system is crucial for nerves to function correctly and for the healthy development of the nervous system.
Is KIF1A-associated neurological disorder always inherited?
KIF1A-associated neurological disorder is a genetic condition, meaning it is caused by a change in the KIF1A gene. It can be inherited from parents (either autosomal dominant or autosomal recessive inheritance), or it can sometimes arise as a new genetic change in an individual with no family history of the condition. Genetic counselling can help explain the specific inheritance pattern for a family.
Can KIF1A-associated neurological disorder be cured?
Currently, there is no cure for KIF1A-associated neurological disorder. Management focuses on treating the symptoms to improve an individual's quality of life. This includes therapies like physiotherapy, occupational therapy, and speech therapy, as well as medications to manage specific symptoms such as muscle stiffness or seizures. Research is ongoing to better understand KAND and develop new treatments.
What support is available for families affected by KIF1A-associated neurological disorder?
Families in the UK can access support through the NHS Genomic Medicine Service, including genetic counselling to understand the condition and its inheritance. Multidisciplinary healthcare teams provide ongoing symptomatic management. Patient support groups and charities specific to KAND or rare neurological disorders can also offer valuable resources, information, and a community for affected families.
How does KIF1A-associated neurological disorder typically progress?
KIF1A-associated neurological disorder is generally progressive, meaning symptoms can evolve or worsen over time, though the rate and specific pattern of progression vary greatly among individuals. Symptoms often begin in infancy or early childhood and can include increasing challenges with movement, balance, and cognitive functions.
References
- Boyle L, Rao L, Kaur S. Genotype and defects in microtubule-based motility correlate with clinical severity in KIF1A-associated neurological disorder. HGG advances. 2021. PMID: 33880452
- Ziegler A, Carroll J, Bain JM. Antisense oligonucleotide therapy in an individual with KIF1A-associated neurological disorder. Nature medicine. 2024. PMID: 39122967
- Nair A, Greeny A, Rajendran R. KIF1A-Associated Neurological Disorder: An Overview of a Rare Mutational Disease. Pharmaceuticals (Basel, Switzerland). 2023. PMID: 37259299
- Morison LD, Vogel AP, Christodoulou J. Understanding speech and language in KIF1A-associated neurological disorder. European journal of human genetics : EJHG. 2026. PMID: 40379967
- Lin Q, Verden D, Christodoulou J. KIF1A-associated neurological disorders: therapeutic opportunities and challenges. European journal of human genetics : EJHG. 2026. PMID: 41310149
- Chen Z, Chai Y, Guo Z. Allele-specific conformational rescue of KIF1A T99M by genetic suppressors in a C. elegans model of KIF1A-associated neurological disorder. Journal of cell science. 2025. PMID: 40964787
- Bernardi K, Ribeiro G, Battaglia N. KIF1A-Associated Neurological Disorder (KAND): Spectrum of Movement and Motor Disorders in a Cohort of 51 Patients. Movement disorders : official journal of the Movement Disorder Society. 2026. PMID: 42500835
- Chiba K, Kita T, Anazawa Y. Insight into the regulation of axonal transport from the study of KIF1A-associated neurological disorder. Journal of cell science. 2023. PMID: 36655764